Repligen Corporation Stock Fair Value – REPLIGEN CORPORATION Reports Second Quarter FY2023 Earnings Results
October 21, 2023
🌥️Earnings Overview
REPLIGEN ($NASDAQ:RGEN): On August 2 2023, REPIGEN CORPORATION released their financial results for the second quarter of FY2023, ending on June 30 2023. Total revenue was USD 159.2 million, a decrease of 23.3% compared to the same quarter of the previous year. Net income for the quarter was USD 20.1 million, a decrease of 59.8% year over year.
Stock Price
On Wednesday, REPLIGEN CORPORATION (NASDAQ: RGEN) reported its second quarter fiscal year 2023 earnings results. The stock opened at $165.3 and closed at $170.5, representing an increase of 2.0% from its previous closing price of $167.1. REPLIGEN CORPORATION reported strong growth in its drug sales and bioprocessing business segments, which drove the significant year-over-year revenue and income increases. The company has also been successful in reducing costs and increasing efficiencies in its operations, leading to improved profitability.
Overall, this was a strong quarter for REPLIGEN CORPORATION, and the company is well-positioned for continued success in the future. Investors will be watching closely as the company continues to execute on its growth strategy and drive long-term shareholder value. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Repligen Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 729.33 | 138.03 | 14.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Repligen Corporation. More…
| Operations | Investing | Financing |
| 160.12 | -233.24 | -13.34 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Repligen Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.55k | 578.08 | 34.85 |
Key Ratios Snapshot
Some of the financial key ratios for Repligen Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 34.1% | 44.2% | 22.3% |
| FCF Margin | ROE | ROA |
| 6.2% | 5.2% | 4.0% |
Analysis – Repligen Corporation Stock Fair Value
At GoodWhale, we have conducted a thorough analysis of REPLIGEN CORPORATION‘s financials. Our proprietary Valuation Line indicated that the fair value of REPLIGEN CORPORATION share is around $231.9. However, the stock is currently traded at a price of $170.5, suggesting that it is undervalued by 26.5%. Therefore, this may be a good opportunity for investors to consider buying REPLIGEN CORPORATION stocks. More…
Peers
The company’s products include proteins and antibodies for the treatment of cancer, central nervous system disorders, and infectious diseases. ReGen Biologics Inc, Tecan Group AG, Stevanato Group SPA are all competitors in the market for developing and commercializing therapeutics.
– ReGen Biologics Inc ($OTCPK:RGBOQ)
Regen Biologics, Inc. is a biotechnology company, which focuses on the development, commercialization, and marketing of products in the orthopedic regenerative medicine field. The company’s products include collagen-based scaffolds for use in orthopedic and sports medicine indications. It operates in the United States, Europe, and Asia. The company was founded by David A. Jay and Stephen J. Sacks in 1997 and is headquartered in Laguna Niguel, CA.
– Tecan Group AG ($OTCPK:TCHBF)
Tecan Group AG is a Swiss-based manufacturer of laboratory instruments and solutions for the life sciences sector. The company has a market cap of 4.54B as of December 2020 and a Return on Equity of 6.13%. Tecan Group AG’s products are used in academic and commercial research laboratories, as well as in clinical diagnostic laboratories. The company’s instruments are used for a variety of applications, including drug discovery and development, biopharmaceutical production, food safety testing, and environmental monitoring.
– Stevanato Group SPA ($NYSE:STVN)
Stevanato Group is a leading provider of integrated solutions for the pharmaceutical and biotech industry. The Group offers a complete range of services, from design and development to manufacturing and packaging of finished products. The Group’s products are used in a wide range of therapeutic areas, including cancer, immunology, infectious diseases and neurology.
Summary
REPLIGEN CORPORATION reported its second quarter fiscal year 2023 earnings on August 2 2023. Total revenue for the quarter was USD 159.2 million, a 23.3% decrease from the same quarter a year prior. Net income declined by 59.8% year over year to USD 20.1 million.
For investors, these results represent a challenging outlook for the future of REPLIGEN CORPORATION and continuing issues in the company’s performance. It is important to monitor the company’s financials and assess the situation before decisions are made regarding investments.
